Global Specific Antiviral Drugs for COVID-19 麻豆原创 Research Report 2023

Publication ID:

PB510234125

Publication Date:

October 20, 2023

Pages:

113

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

The global Specific Antiviral Drugs for COVID-19 market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Specific Antiviral Drugs for COVID-19 market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Specific Antiviral Drugs for COVID-19 market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group
Segment by Type
Tablet
Injection
Segment by Application
Mild Symptom Patient
Critically Ill Patient
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Specific Antiviral Drugs for COVID-19 report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. 麻豆原创 Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: 麻豆原创 Conclusions
Chapter 13: Research Methodology and Data Source

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Specific Antiviral Drugs for COVID-19 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Tablet
1.2.3 Injection
1.3 麻豆原创 by Application
1.3.1 Global Specific Antiviral Drugs for COVID-19 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Mild Symptom Patient
1.3.3 Critically Ill Patient
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Specific Antiviral Drugs for COVID-19 麻豆原创 Perspective (2018-2029)
2.2 Specific Antiviral Drugs for COVID-19 Growth Trends by Region
2.2.1 Global Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Specific Antiviral Drugs for COVID-19 Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Specific Antiviral Drugs for COVID-19 Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Specific Antiviral Drugs for COVID-19 麻豆原创 Dynamics
2.3.1 Specific Antiviral Drugs for COVID-19 Industry Trends
2.3.2 Specific Antiviral Drugs for COVID-19 麻豆原创 Drivers
2.3.3 Specific Antiviral Drugs for COVID-19 麻豆原创 Challenges
2.3.4 Specific Antiviral Drugs for COVID-19 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Specific Antiviral Drugs for COVID-19 Players by Revenue
3.1.1 Global Top Specific Antiviral Drugs for COVID-19 Players by Revenue (2018-2023)
3.1.2 Global Specific Antiviral Drugs for COVID-19 Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Specific Antiviral Drugs for COVID-19 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Specific Antiviral Drugs for COVID-19 Revenue
3.4 Global Specific Antiviral Drugs for COVID-19 麻豆原创 Concentration Ratio
3.4.1 Global Specific Antiviral Drugs for COVID-19 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Specific Antiviral Drugs for COVID-19 Revenue in 2022
3.5 Specific Antiviral Drugs for COVID-19 Key Players Head office and Area Served
3.6 Key Players Specific Antiviral Drugs for COVID-19 Product Solution and Service
3.7 Date of Enter into Specific Antiviral Drugs for COVID-19 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Specific Antiviral Drugs for COVID-19 Breakdown Data by Type
4.1 Global Specific Antiviral Drugs for COVID-19 Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Specific Antiviral Drugs for COVID-19 Forecasted 麻豆原创 Size by Type (2024-2029)
5 Specific Antiviral Drugs for COVID-19 Breakdown Data by Application
5.1 Global Specific Antiviral Drugs for COVID-19 Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Specific Antiviral Drugs for COVID-19 Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Specific Antiviral Drugs for COVID-19 麻豆原创 Size (2018-2029)
6.2 North America Specific Antiviral Drugs for COVID-19 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2018-2023)
6.4 North America Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Specific Antiviral Drugs for COVID-19 麻豆原创 Size (2018-2029)
7.2 Europe Specific Antiviral Drugs for COVID-19 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2018-2023)
7.4 Europe Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Specific Antiviral Drugs for COVID-19 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Specific Antiviral Drugs for COVID-19 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Specific Antiviral Drugs for COVID-19 麻豆原创 Size (2018-2029)
9.2 Latin America Specific Antiviral Drugs for COVID-19 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Specific Antiviral Drugs for COVID-19 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Specific Antiviral Drugs for COVID-19 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Specific Antiviral Drugs for COVID-19 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Specific Antiviral Drugs for COVID-19 Introduction
11.1.4 Sanofi Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.1.5 Sanofi Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Specific Antiviral Drugs for COVID-19 Introduction
11.2.4 Novartis Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 Shanghai Zhongxisanwei
11.3.1 Shanghai Zhongxisanwei Company Detail
11.3.2 Shanghai Zhongxisanwei Business Overview
11.3.3 Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Introduction
11.3.4 Shanghai Zhongxisanwei Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.3.5 Shanghai Zhongxisanwei Recent Development
11.4 Teva
11.4.1 Teva Company Detail
11.4.2 Teva Business Overview
11.4.3 Teva Specific Antiviral Drugs for COVID-19 Introduction
11.4.4 Teva Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.4.5 Teva Recent Development
11.5 Zydus Cadila
11.5.1 Zydus Cadila Company Detail
11.5.2 Zydus Cadila Business Overview
11.5.3 Zydus Cadila Specific Antiviral Drugs for COVID-19 Introduction
11.5.4 Zydus Cadila Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.5.5 Zydus Cadila Recent Development
11.6 Mylan
11.6.1 Mylan Company Detail
11.6.2 Mylan Business Overview
11.6.3 Mylan Specific Antiviral Drugs for COVID-19 Introduction
11.6.4 Mylan Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.6.5 Mylan Recent Development
11.7 Apotex
11.7.1 Apotex Company Detail
11.7.2 Apotex Business Overview
11.7.3 Apotex Specific Antiviral Drugs for COVID-19 Introduction
11.7.4 Apotex Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.7.5 Apotex Recent Development
11.8 Advanz Pharma
11.8.1 Advanz Pharma Company Detail
11.8.2 Advanz Pharma Business Overview
11.8.3 Advanz Pharma Specific Antiviral Drugs for COVID-19 Introduction
11.8.4 Advanz Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.8.5 Advanz Pharma Recent Development
11.9 Sun Pharma
11.9.1 Sun Pharma Company Detail
11.9.2 Sun Pharma Business Overview
11.9.3 Sun Pharma Specific Antiviral Drugs for COVID-19 Introduction
11.9.4 Sun Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.9.5 Sun Pharma Recent Development
11.10 Kyung Poong
11.10.1 Kyung Poong Company Detail
11.10.2 Kyung Poong Business Overview
11.10.3 Kyung Poong Specific Antiviral Drugs for COVID-19 Introduction
11.10.4 Kyung Poong Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.10.5 Kyung Poong Recent Development
11.11 Ipca Laboratories
11.11.1 Ipca Laboratories Company Detail
11.11.2 Ipca Laboratories Business Overview
11.11.3 Ipca Laboratories Specific Antiviral Drugs for COVID-19 Introduction
11.11.4 Ipca Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.11.5 Ipca Laboratories Recent Development
11.12 Hanlim Pharmaceutical
11.12.1 Hanlim Pharmaceutical Company Detail
11.12.2 Hanlim Pharmaceutical Business Overview
11.12.3 Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction
11.12.4 Hanlim Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.12.5 Hanlim Pharmaceutical Recent Development
11.13 Bristol Laboratories
11.13.1 Bristol Laboratories Company Detail
11.13.2 Bristol Laboratories Business Overview
11.13.3 Bristol Laboratories Specific Antiviral Drugs for COVID-19 Introduction
11.13.4 Bristol Laboratories Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.13.5 Bristol Laboratories Recent Development
11.14 Bayer
11.14.1 Bayer Company Detail
11.14.2 Bayer Business Overview
11.14.3 Bayer Specific Antiviral Drugs for COVID-19 Introduction
11.14.4 Bayer Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.14.5 Bayer Recent Development
11.15 Rising Pharmaceutical
11.15.1 Rising Pharmaceutical Company Detail
11.15.2 Rising Pharmaceutical Business Overview
11.15.3 Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction
11.15.4 Rising Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.15.5 Rising Pharmaceutical Recent Development
11.16 Shanghai Pharma
11.16.1 Shanghai Pharma Company Detail
11.16.2 Shanghai Pharma Business Overview
11.16.3 Shanghai Pharma Specific Antiviral Drugs for COVID-19 Introduction
11.16.4 Shanghai Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.16.5 Shanghai Pharma Recent Development
11.17 Sichuan Sunny Hope
11.17.1 Sichuan Sunny Hope Company Detail
11.17.2 Sichuan Sunny Hope Business Overview
11.17.3 Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Introduction
11.17.4 Sichuan Sunny Hope Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.17.5 Sichuan Sunny Hope Recent Development
11.18 Guangzhou Baiyunshan Guanghua Pharmaceutical
11.18.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Company Detail
11.18.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Business Overview
11.18.3 Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Introduction
11.18.4 Guangzhou Baiyunshan Guanghua Pharmaceutical Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.18.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Development
11.19 CSPC Group
11.19.1 CSPC Group Company Detail
11.19.2 CSPC Group Business Overview
11.19.3 CSPC Group Specific Antiviral Drugs for COVID-19 Introduction
11.19.4 CSPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.19.5 CSPC Group Recent Development
11.20 KPC Group
11.20.1 KPC Group Company Detail
11.20.2 KPC Group Business Overview
11.20.3 KPC Group Specific Antiviral Drugs for COVID-19 Introduction
11.20.4 KPC Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.20.5 KPC Group Recent Development
11.21 Jinghua Pharmaceutical Group
11.21.1 Jinghua Pharmaceutical Group Company Detail
11.21.2 Jinghua Pharmaceutical Group Business Overview
11.21.3 Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction
11.21.4 Jinghua Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.21.5 Jinghua Pharmaceutical Group Recent Development
11.22 Zhongsheng Pharma
11.22.1 Zhongsheng Pharma Company Detail
11.22.2 Zhongsheng Pharma Business Overview
11.22.3 Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Introduction
11.22.4 Zhongsheng Pharma Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.22.5 Zhongsheng Pharma Recent Development
11.23 North China Pharmaceutical Group
11.23.1 North China Pharmaceutical Group Company Detail
11.23.2 North China Pharmaceutical Group Business Overview
11.23.3 North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Introduction
11.23.4 North China Pharmaceutical Group Revenue in Specific Antiviral Drugs for COVID-19 Business (2018-2023)
11.23.5 North China Pharmaceutical Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Sanofi
Novartis
Shanghai Zhongxisanwei
Teva
Zydus Cadila
Mylan
Apotex
Advanz Pharma
Sun Pharma
Kyung Poong
Ipca Laboratories
Hanlim Pharmaceutical
Bristol Laboratories
Bayer
Rising Pharmaceutical
Shanghai Pharma
Sichuan Sunny Hope
Guangzhou Baiyunshan Guanghua Pharmaceutical
CSPC Group
KPC Group
Jinghua Pharmaceutical Group
Zhongsheng Pharma
North China Pharmaceutical Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.